Axura: Uses, Dosage & Side Effects

What Is Axura and What Is It Used For?

Alzheimer's disease is a progressive neurodegenerative condition that affects millions of people worldwide. It is the most common cause of dementia, accounting for 60–80% of all dementia cases according to the World Health Organization (WHO). As the disease progresses, patients experience worsening memory loss, cognitive decline, changes in behavior, and increasing difficulty with daily activities. The condition places an enormous burden on patients, families, and healthcare systems globally.

Memantine, the active ingredient in Axura, was first approved for use in Europe in 2002 and subsequently received FDA approval in the United States in 2003 (marketed as Namenda). It represents the second major class of drugs approved for Alzheimer's disease treatment, the first being cholinesterase inhibitors such as donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne). While cholinesterase inhibitors are primarily indicated for mild to moderate Alzheimer's disease, memantine is specifically designed for patients with moderate to severe stages of the condition.

The mechanism of action of memantine is fundamentally different from cholinesterase inhibitors. In Alzheimer's disease, there is abnormal, chronically elevated glutamate activity at NMDA receptors. This sustained overstimulation, known as excitotoxicity, damages and destroys neurons, contributing to the cognitive decline seen in the disease. Memantine acts as a voltage-dependent, moderate-affinity, uncompetitive NMDA receptor antagonist. It blocks the channel under conditions of excessive stimulation while allowing normal physiological signaling to continue. This selective blocking action protects neurons from glutamate-mediated excitotoxicity without disrupting normal neurotransmission needed for learning and memory.

Clinical trials have demonstrated that memantine provides statistically significant benefits in cognition, global clinical impression, activities of daily living, and behavior in patients with moderate to severe Alzheimer's disease. A comprehensive Cochrane systematic review confirmed these findings, showing modest but clinically meaningful improvements across multiple outcome domains. The benefits are typically observed within one to three months of starting treatment at the full therapeutic dose.

What Should You Know Before Taking Axura?

Contraindications

Axura must not be taken by individuals who are hypersensitive (allergic) to memantine hydrochloride or to any of the excipients contained in the formulation. While true allergies to memantine are rare, any previous adverse reaction to the medication or its components should be reported to a healthcare provider before treatment is considered. The film-coated tablets contain lactose monohydrate, so patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine.

Warnings and Precautions

Several medical conditions require special caution when using Axura. Your physician needs to know if you have any of the following:

• Epilepsy or history of seizures: Memantine may lower the seizure threshold in some patients. Patients with a history of convulsions or predisposing factors for epilepsy should be closely monitored during treatment.
• Kidney (renal) impairment: Since memantine is primarily eliminated by the kidneys, patients with moderate renal impairment (creatinine clearance 30–49 mL/min) may require a dose reduction to 10 mg daily. Patients with severe renal impairment (creatinine clearance 5–29 mL/min) should receive a maximum daily dose of 10 mg. Regular monitoring of renal function is recommended during treatment.
• Conditions that raise urine pH: The renal elimination of memantine is reduced in alkaline urine. Conditions such as renal tubular acidosis, urinary tract infections caused by Proteus bacteria, or a strict vegetarian diet can alkalinize the urine and potentially increase memantine levels. Patients should be monitored accordingly.
• Recent heart attack, heart failure, or uncontrolled hypertension: Clinical experience in patients with these conditions is limited. These patients should be carefully observed during treatment.
• Liver impairment: While no specific dose recommendations exist for mild to moderate hepatic impairment, caution is advised. Axura is not recommended in patients with severe hepatic impairment as there is insufficient clinical data.

Pregnancy and Breastfeeding

Axura is not recommended during pregnancy unless clearly necessary and the potential benefit to the mother justifies the potential risk to the fetus. There are no adequate data from the use of memantine in pregnant women. Animal studies have shown potential effects on intrauterine growth at exposure levels comparable to or slightly higher than human therapeutic doses. The potential risk to humans is unknown, and the decision to use Axura during pregnancy must be made on a case-by-case basis by a specialist physician.

It is not known whether memantine is excreted in human breast milk. Given the lipophilicity of the substance, passage into breast milk is considered likely. Women taking memantine should not breastfeed. If breastfeeding is considered essential, the healthcare provider should weigh the benefit of nursing against the potential risk to the infant.

It is important to note that Alzheimer's disease predominantly affects older adults, making pregnancy and breastfeeding less commonly relevant clinical scenarios for this particular medication. However, memantine is occasionally used off-label for other neurological conditions, in which case reproductive considerations become more important.

How Does Axura Interact with Other Drugs?

Drug interactions with memantine can affect both the efficacy and safety of treatment. Understanding these interactions is crucial for safe use of Axura. The following sections describe the most clinically significant interactions that healthcare providers and patients should be aware of.

Major Interactions

Certain medications should not be used together with memantine or require careful monitoring due to the risk of serious adverse effects:

• Amantadine: Both amantadine and memantine are NMDA receptor antagonists. Concomitant use increases the risk of central nervous system (CNS) side effects including psychosis, confusion, and hallucinations. The combination should generally be avoided.
• Ketamine: As another NMDA receptor antagonist, ketamine used with memantine may enhance CNS adverse effects. Concurrent use is not recommended.
• Dextromethorphan: This common cough suppressant also acts on NMDA receptors. Combined use with memantine may increase the risk of CNS effects, and patients should consult their physician before using cough medicines containing dextromethorphan.

Minor Interactions

Several other medications may interact with memantine in ways that are generally manageable with appropriate monitoring:

The interaction profile of memantine also extends to drugs that share the same renal cation transport system. Medications such as procainamide, quinidine, quinine, and nicotine utilize the same transport mechanism and could theoretically interact with memantine, though clinical significance appears to be low. Nevertheless, patients taking any of these medications should inform their physician so that appropriate monitoring can be established.

It is worth noting that memantine does not inhibit CYP450 enzymes (1A2, 2A6, 2C9, 2D6, 2E1, 3A4) in vitro, making clinically relevant metabolic interactions with drugs metabolized by these enzyme systems unlikely. This favorable pharmacokinetic profile makes memantine relatively well-suited for use in elderly patients who are often taking multiple medications.

What Is the Correct Dosage of Axura?

Axura should always be initiated and supervised by a physician experienced in the diagnosis and treatment of Alzheimer's disease. Treatment should only be started if a caregiver is available who will regularly monitor the intake of the medication by the patient. Diagnosis should be made in accordance with current guidelines, and the patient's tolerance of memantine should be regularly reassessed, preferably within three months after the start of treatment.

Adults

The dose of Axura is gradually increased during the first few weeks of treatment to reduce the risk of side effects. This process, known as dose titration, follows a specific schedule:

Axura tablets can be taken with or without food. They should be swallowed whole with a glass of water. The tablets should not be crushed or chewed. It is recommended to take the medication at the same time each day to maintain consistent blood levels and to help caregivers remember administration.

Children and Adolescents

Axura is not recommended for use in children and adolescents under 18 years of age. Alzheimer's disease does not occur in pediatric populations, and there is no relevant indication for use in this age group. Memantine has not been studied in children for this indication, and therefore no dosage recommendations can be made.

Elderly Patients

No dose adjustment is required based on age alone. However, elderly patients often have reduced kidney function, which may affect memantine clearance. Renal function should be assessed before starting treatment and periodically during therapy. For patients with moderate renal impairment (creatinine clearance 30–49 mL/min), the recommended dose is 10 mg per day. This dose may be increased to 20 mg per day based on individual tolerability after at least 7 days of treatment at each dose level. For patients with severe renal impairment (creatinine clearance 5–29 mL/min), the daily dose should not exceed 10 mg.

Missed Dose

If a dose is missed, the patient or caregiver should take it as soon as they remember on the same day. However, if it is almost time for the next scheduled dose, the missed dose should be skipped entirely. A double dose should never be taken to make up for a forgotten dose, as this increases the risk of side effects. If the patient misses several consecutive doses, the prescribing physician should be consulted before resuming treatment, as a new titration period may be necessary.

Overdose

In the event of a suspected overdose, medical attention should be sought immediately. Symptoms of memantine overdose may include restlessness, psychosis, visual hallucinations, drowsiness or somnolence, stupor, and loss of consciousness. In reported cases of overdose with doses up to 400 mg, patients experienced CNS effects that were generally reversible with supportive care. There is no specific antidote for memantine overdose. Treatment is symptomatic and supportive. Standard clinical measures to remove unabsorbed drug (such as gastric lavage, activated charcoal) may be considered. Memantine is not efficiently removed by hemodialysis due to its large volume of distribution.

What Are the Side Effects of Axura?

Side effects reported in clinical trials and post-marketing surveillance have been categorized by frequency. Understanding these frequencies helps patients and caregivers know what to expect and when to seek medical attention. The frequency categories used are based on the following conventions: very common (affects more than 1 in 10 patients), common (1 in 10 to 1 in 100), uncommon (1 in 100 to 1 in 1,000), and rare (fewer than 1 in 1,000).

Alzheimer's disease itself is associated with depression, suicidal ideation, and vomiting. These symptoms have been reported in patients treated with memantine in clinical trials. It can be difficult to determine whether these events are related to the medication or the underlying disease process. Caregivers should be vigilant for any behavioral changes and report concerns to the treating physician promptly.

In clinical trials, the overall incidence of adverse events was similar between memantine-treated patients and those receiving placebo. Adverse events were generally mild to moderate in severity. The most frequent reason for discontinuation in memantine-treated patients was dizziness, which occurred in approximately 1.5% of patients in pivotal trials. Overall, memantine is considered to have a favorable safety profile compared to many other medications used in elderly patients.

How Should You Store Axura?

Proper storage of Axura is essential to maintain the medication's effectiveness and safety throughout its shelf life. The film-coated tablets should be stored at a temperature not exceeding 25°C (77°F). They should be kept in the original blister packaging until use to protect them from moisture and light degradation. Do not store in the bathroom or near a kitchen sink where humidity levels are high.

The expiration date printed on the packaging refers to the last day of the stated month. Do not use Axura after this date, as the chemical stability and potency of the medication can no longer be guaranteed. Expired medications should be returned to a pharmacy for proper disposal. Do not dispose of medicines via wastewater or household waste, as this can have harmful effects on the environment.

For caregivers managing medication for Alzheimer's patients, it is advisable to use a pill organizer to track daily doses. However, tablets removed from the original packaging should be used within a reasonable timeframe (typically within one month) and stored in a cool, dry place. Always check that tablets appear intact and have not changed color or developed an unusual odor before administration.

What Does Axura Contain?

The active substance in Axura is memantine hydrochloride. Each tablet strength contains exactly the labeled amount: 5 mg, 10 mg, 15 mg, or 20 mg of memantine hydrochloride, equivalent to 4.15 mg, 8.31 mg, 12.46 mg, and 16.62 mg of memantine base, respectively.

The other ingredients (excipients) in the tablet core typically include:

• Lactose monohydrate – a filler/diluent (important for patients with lactose intolerance)
• Microcrystalline cellulose – a binder and filler
• Colloidal anhydrous silica – a glidant for manufacturing
• Talc – a glidant and anti-adherent
• Magnesium stearate – a lubricant

The film coating typically contains:

• Methacrylic acid – ethyl acrylate copolymer – the coating polymer
• Sodium lauryl sulfate – a surfactant
• Polysorbate 80 – an emulsifier
• Triethyl citrate – a plasticizer
• Simethicone emulsion – an anti-foaming agent

The different tablet strengths are typically distinguished by their shape and color for easier identification. The 10 mg tablets are usually white to off-white, oblong, biconvex film-coated tablets with a break line on one side. The break line on the 10 mg tablet is only intended to facilitate breaking for ease of swallowing and not to divide the tablet into equal doses. Patients should always follow their prescribing physician's instructions regarding dosage and not attempt to split tablets to create custom doses unless specifically directed to do so.